From 6 to 8 November 2025, the OphtAI team (Evolucare Group) looks forward to seeing you at the AIMO-SISO congress in Italy, at the stand shared with Topcon Italy, a global player in ophthalmic imaging. Join us there to discover our latest innovations in artificial intelligence applied to ophthalmology.
🔍 Major advances in the diagnosis of retinal diseases
OphtAI will present its cutting-edge solutions for the automated detection of eye conditions such as:
- Diabetic retinopathy (detection and grading)
- Glaucoma
- Age-related macular degeneration (AMD) and drusen
- Naevi
- Retinal vein occlusion (CRVO + BRVO)
- Macular hole, epiretinal membrane
- Cataracts, severe myopia, retinitis pigmentosa
- Hypertensive retinopathy
- Laser photocoagulation scars, pigment migration
- Alteration of the retinal pigment epithelium
- Normal/abnormal eye (patented technology)
- MIDD
These innovations are the result of close collaboration between Evolucare, AP-HP, UBO and Adcis, guaranteeing powerful and clinically validated algorithms.
💡 MyOphtAI: simplicity, autonomy, efficiency
In response to the increasing pressure on healthcare professionals, OphtAI offers MyOphtAI, a monthly subscription service with no commitment, including:
- Free trial
- Unlimited use
- Zero handling, zero clicks: files are sorted automatically
👉 Test MyOphtAI for free and discover a new way of working that is smoother and more efficient.
🤝 A robust ecosystem of partners and integrators
OphtAI relies on a network of recognised technology partners and integrators:
- Topcon, Optomed, Crystalvue, Umami View
- Oplus, Téo, Area
This complementarity ensures optimal interoperability and rapid adoption in the field.
📍 Come and experience OphtAI at our stand no. 30.
On site, you can:
- Discover real-world use cases
- Talk to our AI specialists
- Test our solutions in real-world situations
A unique opportunity to understand how AI can strengthen the work of healthcare professionals, improve early diagnosis and reduce inequalities in access to eye care.
🔁 A constant commitment to innovation
Back in 2024, OphtAI had already made a name for itself at the 4th Retina and Diabetes Day, bringing together ophthalmologists and experts to discuss the challenges of AI in screening. This initiative is consistent with our vision, as expressed in the #Pact4all project: a seamless, continuous care pathway that is accessible to all.